Skip to content

Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?

Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00811746
Enrollment
90
Registered
2008-12-19
Start date
2008-12-31
Completion date
2010-10-31
Last updated
2013-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

obstructive sleep apnea, eszopiclone, ramelteon, polysomnography

Brief summary

This study is being conducted to determine if eszopiclone is as effective as ramelteon when used as a pre-medication (sleeping pill) in sleep studies performed to diagnose and treat sleep apnea.

Detailed description

Many Veterans suffer from sleep disordered breathing with a high prevalence of undiagnosed obstructive sleep apnea. One test that can be effective in the diagnosis of sleep apnea is the polysomnogram (PSG). Split-night PSG consists of a diagnostic phase in the first half of the night and a continuous positive airway pressure titration (CPAP) in the second half of the night. CPAP is the standard, most effective therapy for obstructive sleep apnea. Due to the unfamiliar sleep environment of the laboratory and instrumentation that must be used (application of electroencephalogram leads), patients are frequently not able to sleep adequately. In these cases, the PSG must be repeated. Oral hypnotic agents are often used as a pre-medication to increase the yield of PSG in an attempt to decrease the need for repeat studies. Numerous data is available on the effects of premedication with oral short-acting hypnotics on PSG quality and efficacy of CPAP titration. In one study, eszopiclone, a nonbenzodiazepine gaba-receptor agonist short-acting hypnotic, has been shown to improve PSG quality and CPAP titration. Another short-acting hypnotic, ramelteon, was recently approved by FDA but the effects of ramelteon in improving PSG quality and efficacy of CPAP titration are unclear. The advantage of ramelteon over eszopiclone is the lack of drug dependency or abuse potential. This study aims to evaluate the efficacy of ramelteon compared to eszopiclone when administered prior to split-night PSG and CPAP titration.

Interventions

8 mg taken orally 30 minutes before a split-night PSG

DRUGLunesta (Eszopiclone)

3 mg taken orally 30 minutes before the start of a split-night PSG

Chart review matched for demographics and comorbidities of the study drug groups.

Sponsors

Southern California Institute for Research and Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Referred by VA Long Beach Sleep Clinic at their initial evaluation during outpatient consultation for suspect obstructive sleep apnea.

Exclusion criteria

* Sleep disorders other than obstructive sleep apnea * No prior PSG * Uncontrolled medical condition * Prior known adverse reaction to eszopiclone or ramelteon * Liver disfunction * Current alcohol abuser * Current illicit drug abuser * Alcohol consumption 12 hours prior to polysomnography * Decompensated psychiatric disorders * Severe dementia * Concomitant use of benzodiazepines, trazodone, narcotics, barbiturates or other medications with sedative or hypnotic effects

Design outcomes

Primary

MeasureTime frame
Non-usable and poor quality PSGs and CPAP intoleranceThe morning following the PSG

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026